PL2268635T3 - Związki heterocykliczne - Google Patents

Związki heterocykliczne

Info

Publication number
PL2268635T3
PL2268635T3 PL08874003T PL08874003T PL2268635T3 PL 2268635 T3 PL2268635 T3 PL 2268635T3 PL 08874003 T PL08874003 T PL 08874003T PL 08874003 T PL08874003 T PL 08874003T PL 2268635 T3 PL2268635 T3 PL 2268635T3
Authority
PL
Poland
Prior art keywords
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
PL08874003T
Other languages
English (en)
Inventor
Chi-Feng Yen
Cheng-Kung Hu
Chang-Pin Huang
Ying-Huey Huang
Gholam Hossein Hakimelahi
Chi-Hsin Richard King
Original Assignee
Taigen Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taigen Biotechnology Co Ltd filed Critical Taigen Biotechnology Co Ltd
Publication of PL2268635T3 publication Critical patent/PL2268635T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL08874003T 2008-04-21 2008-11-03 Związki heterocykliczne PL2268635T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4649608P 2008-04-21 2008-04-21
PCT/US2008/082202 WO2009131598A1 (en) 2008-04-21 2008-11-03 Heterocyclic compounds
EP08874003.0A EP2268635B1 (en) 2008-04-21 2008-11-03 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
PL2268635T3 true PL2268635T3 (pl) 2015-11-30

Family

ID=41201620

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08874003T PL2268635T3 (pl) 2008-04-21 2008-11-03 Związki heterocykliczne

Country Status (20)

Country Link
US (1) US8372849B2 (pl)
EP (1) EP2268635B1 (pl)
JP (1) JP5661607B2 (pl)
KR (1) KR101579999B1 (pl)
CN (1) CN101565404B (pl)
AU (1) AU2008355098B2 (pl)
CA (1) CA2720229C (pl)
CY (1) CY1116802T1 (pl)
DK (1) DK2268635T3 (pl)
EA (1) EA019289B1 (pl)
ES (1) ES2545731T3 (pl)
HR (1) HRP20150932T2 (pl)
HU (1) HUE025179T2 (pl)
NZ (1) NZ588989A (pl)
PL (1) PL2268635T3 (pl)
PT (1) PT2268635E (pl)
SI (1) SI2268635T1 (pl)
TW (1) TWI444188B (pl)
WO (1) WO2009131598A1 (pl)
ZA (1) ZA201008262B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201021855A (en) * 2008-11-13 2010-06-16 Taigen Biotechnology Co Ltd Lyophilization formulation
CN103204816B (zh) * 2012-01-16 2016-04-27 中国人民解放军军事医学科学院毒物药物研究所 哌嗪基嘧啶类衍生物及其制备方法和用途
EP2836214B1 (en) * 2012-04-11 2018-06-27 Acerta Pharma B.V. Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
AU2015321654B2 (en) 2014-09-22 2019-10-31 National Health Research Institutes Heterocyclic compounds and use thereof
US9375406B2 (en) * 2014-09-30 2016-06-28 Taigen Biotechnology Co., Ltd. Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor
TWI620748B (zh) 2016-02-05 2018-04-11 National Health Research Institutes 氨基噻唑化合物及其用途
CN110381949B (zh) 2017-01-10 2023-12-08 财团法人卫生研究院 杂环化合物及其用途
CN109553604B (zh) * 2017-09-25 2021-08-27 盛世泰科生物医药技术(苏州)有限公司 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
CN108794414B (zh) * 2018-06-22 2021-01-01 浙江大学 芳酰胺基取代的均三嗪类化合物及制备和应用
CN116120195B (zh) * 2022-12-29 2025-02-25 长兴宜生药物科技有限公司 一种催化制备培哚普利中间体的方法
PL247377B1 (pl) * 2023-06-29 2025-06-23 Politechnika Krakowska Im Tadeusza Kosciuszki Nowa pochodna 1,3,5-triazyny i jej zastosowanie

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6029A (en) * 1849-01-16 Method of directing the scoops in dredging machines
US3007A (en) * 1843-03-21 Improvement in salt-boilers
US5034560A (en) 1990-10-19 1991-07-23 The Standard Oil Company Synthesis of ethylamines
DE69213240T2 (de) 1991-07-04 1997-04-24 Immunodex K/S, Glostrup Wasserlösliche reagenzien und konjugate auf polymerbasis, die vom divinylsulfon abgeleitete reste enthalten
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
IL112795A (en) 1994-03-04 2001-01-28 Astrazeneca Ab Peptide derivatives as antithrombic agents their preparation and pharmaceutical compositions containing them
WO1997020823A2 (en) 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
EP1007073A4 (en) 1996-06-04 2002-03-27 Synaptic Pharma Corp METHODS OF MODIFYING FOOD BEHAVIOR, COMPOUNDS USEFUL IN SAID METHODS, AND DNA ENCODING A HYPOTHALAMIC NEUROPEPTIDE Y / PEPTIDE YY Y5 RECEPTOR
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
AR038955A1 (es) * 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
WO1999050249A2 (en) 1998-04-01 1999-10-07 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
US6420354B1 (en) 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
EA200100255A1 (ru) 1998-08-20 2002-02-28 Агурон Фармасьютикалз, Инк. НЕПЕПТИДНЫЕ СРЕДСТВА GnRH, СПОСОБЫ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ИХ ПОЛУЧЕНИЯ
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
TW550258B (en) 1999-05-31 2003-09-01 Hoffmann La Roche 4-phenyl-pyrimidine derivatives
JP2003519143A (ja) * 1999-12-28 2003-06-17 ファーマコピーア，インコーポレーティッド ピリミジン及びトリアジン系キナーゼ阻害剤
WO2002068415A1 (en) 2000-12-21 2002-09-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
KR20100107509A (ko) * 2001-09-14 2010-10-05 9222-9129 퀘벡 인코포레이티드 히스톤 데아세틸라아제의 억제제
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
WO2003026664A1 (en) 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
US7544690B2 (en) 2001-10-01 2009-06-09 Taisho Pharmaceutical Co., Ltd. MCH receptor antagonists
ES2373226T3 (es) 2002-06-28 2012-02-01 Astellas Pharma Inc. Derivado de diaminopirimidincarboxamida.
JP4666256B2 (ja) * 2002-12-10 2011-04-06 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
ATE440087T1 (de) 2003-01-30 2009-09-15 Boehringer Ingelheim Pharma 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
CN100402495C (zh) 2003-09-22 2008-07-16 弗·哈夫曼-拉罗切有限公司 氨基烷基酰胺取代的环己基衍生物
MXPA06010900A (es) * 2004-03-26 2007-02-21 Methylgene Inc Inhibidores de histona desacetilasa.
DK2447252T3 (da) 2004-05-23 2020-03-16 Hmi Medical Innovations Llc Theramuteinmodulatorer
JP2006124387A (ja) * 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
EA015890B1 (ru) * 2005-06-14 2011-12-30 Тайджен Байотекнолоджи Ко. Лтд. Производные пиримидина
NZ566744A (en) 2005-08-29 2011-04-29 Gerard M Housey Theramutein modulators
RU2436776C2 (ru) 2005-09-27 2011-12-20 Айрм Ллк ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT
US20090275070A1 (en) 2005-11-23 2009-11-05 Housey Gerard M Compounds and Methods of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators
CA2644356A1 (en) 2006-03-16 2007-09-27 Novartis Ag Heterocyclic organic compounds for the treatment of in particular melanoma
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
US8222256B2 (en) * 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators

Also Published As

Publication number Publication date
CA2720229C (en) 2015-02-17
NZ588989A (en) 2012-03-30
KR101579999B1 (ko) 2015-12-23
SI2268635T1 (sl) 2015-10-30
HUE025179T2 (en) 2016-02-29
JP5661607B2 (ja) 2015-01-28
PT2268635E (pt) 2015-10-06
WO2009131598A1 (en) 2009-10-29
ZA201008262B (en) 2011-07-27
TW200944206A (en) 2009-11-01
EP2268635B1 (en) 2015-06-10
CN101565404A (zh) 2009-10-28
AU2008355098B2 (en) 2012-11-15
EP2268635A1 (en) 2011-01-05
HRP20150932T2 (hr) 2017-10-20
EA201071221A1 (ru) 2011-08-30
ES2545731T3 (es) 2015-09-15
CN101565404B (zh) 2012-12-05
JP2011519360A (ja) 2011-07-07
AU2008355098A1 (en) 2009-10-29
EA019289B1 (ru) 2014-02-28
CA2720229A1 (en) 2009-10-29
EP2268635A4 (en) 2012-02-22
KR20110008085A (ko) 2011-01-25
HK1138269A1 (en) 2010-08-20
CY1116802T1 (el) 2017-03-15
TWI444188B (zh) 2014-07-11
US20090264339A1 (en) 2009-10-22
US8372849B2 (en) 2013-02-12
HRP20150932T1 (xx) 2015-10-09
DK2268635T3 (en) 2015-09-14

Similar Documents

Publication Publication Date Title
GEP20135844B (en) Heterocyclic compound
IL212186A0 (en) Fungicidal heterocyclic compounds
GB0800035D0 (en) Compounds
IL208203A0 (en) Heterocyclic derivatives
AP2010005364A0 (en) Novel heterocyclic compounds.
IL231955B (en) Tetracycline compounds are substituted at the 7c position with fluorine
GB0804702D0 (en) Compounds
ZA201008262B (en) Heterocyclic compounds
GB0800367D0 (en) Compounds
GB0921210D0 (en) Novel heterocyclic derivatives
GB0801220D0 (en) Compounds
GB0801265D0 (en) Compounds
GB0919817D0 (en) Heterocyclic compounds
GB0919816D0 (en) Heterocyclic compounds
IL210015A0 (en) Substituted cyclohexylidene-ethylidene-octahydro-indene compounds
GB0800454D0 (en) Compounds
GB0800961D0 (en) Compounds
GB0801219D0 (en) Compounds
GB0800841D0 (en) Compounds
GB0800455D0 (en) Compounds
GB0801596D0 (en) Compounds
GB0802191D0 (en) Compounds
GB0802192D0 (en) Compounds
GB0802231D0 (en) Compounds
GB0802586D0 (en) Compounds